CC cell lines HCT116 (ATCC® CCL-247) and HT29 (ATCC® HTB-38) were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA), and human normal colon epithelial cell line NCM 460 (CM-H203) was purchased from GAINING BIOLOGICAL (Shanghai, China). All cells were cultured in Roswell Park Memorial Institute 1640 Medium (RPMI1640; Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibco, Grand Island, NY, USA) at 37°C with 5% CO2.
The overexpression plasmid of MALAT1 (LV-MALAT1), the small interfering RNA (si-RNA) against MALAT1 (si-MALAT1-1 and si-MALAT1-2), si-RNA against STC1 (si-STC1), and the negative controls (LV-NC and si-NC) were purchased from GenePharma (Shanghai, China). The targeting sequences for si-MALAT1-1, si-MALAT1-2, si-STC1 and si-NC were 5ʹ-GGCAAUGUUUUACACUAUUTT-3ʹ, 5ʹ-CACAGGGAAAGCGAGTGGTTGGTAA-3ʹ, 5ʹ-CTGCTTAAACAAAGCAGTATA-3ʹ and 5ʹ-UUCUCCGAACGUGUCACGUTT-3ʹ, respectively. In addition, miR-101-3p mimics, miR-101-3p inhibitor and the negative controls (mimics NC and inhibitor NC) were purchased from Ribobio (Guangzhou, China). When reaching 80% confluence, cells were transfected with the above agents using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) for 48 h.
The overexpression plasmid of MALAT1 (LV-MALAT1), the small interfering RNA (si-RNA) against MALAT1 (si-MALAT1-1 and si-MALAT1-2), si-RNA against STC1 (si-STC1), and the negative controls (LV-NC and si-NC) were purchased from GenePharma (Shanghai, China). The targeting sequences for si-MALAT1-1, si-MALAT1-2, si-STC1 and si-NC were 5ʹ-GGCAAUGUUUUACACUAUUTT-3ʹ, 5ʹ-CACAGGGAAAGCGAGTGGTTGGTAA-3ʹ, 5ʹ-CTGCTTAAACAAAGCAGTATA-3ʹ and 5ʹ-UUCUCCGAACGUGUCACGUTT-3ʹ, respectively. In addition, miR-101-3p mimics, miR-101-3p inhibitor and the negative controls (mimics NC and inhibitor NC) were purchased from Ribobio (Guangzhou, China). When reaching 80% confluence, cells were transfected with the above agents using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) for 48 h.